Skip to Content
Merck
CN

Key Documents

View All Documentation

SML0123

Deflazacort

≥98% (HPLC)

Synonym(s):

(11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 11β,21-dihydroxy-2′-methyl-5′βH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2′-acetate, DL-458-IT, L-5458, azacort, oxazacort, pregna-1,4-diene-11β,21-diol-3,20-dione[17α,16α-d]-2′-methyloxazoline 21-acetate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C25H31NO6
CAS Number:
14484-47-0
Molecular Weight:
441.52
NACRES:
NA.77
PubChem Substance ID:
329825173
UNSPSC Code:
51111800
EC Number:
238-483-7
MDL number:
MFCD00866106
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to tan

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C

InChI

1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

InChI key

FBHSPRKOSMHSIF-GRMWVWQJSA-N

Gene Information

human ... NR3C1(2908)

Biochem/physiol Actions

Deflazacort is an Anti-inflammatory glucocorticoid
Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.

Still not finding the right product?

Explore all of our products under Deflazacort

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

监管及禁止进口产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000479246
0000375408
0000366529
0000375408
0000366529

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elena Stacy Mazzone et al.
PloS one, 8(1), e52512-e52512 (2013-01-18)
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affected by Duchenne muscular dystrophy, ii) to establish the difference between the first and the second year results and iii) to
Elaine C da Silva et al.
Arquivos de neuro-psiquiatria, 70(3), 191-195 (2012-03-07)
To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). Thirty-three patients with DMD
Corrado Angelini et al.
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 31(1), 9-15 (2012-06-05)
Steroids have been used since two decades and several trials were conducted to establish their efficacy in DMD patients with various regimens. The clinical outcomes showed increased function in the treated boys, and in a single trial with deflazacort, prolongation
View All Related Papers

Global Trade Item Number

SKUGTIN
SML0123-10MG04061837076916
SML0123-50MG04061837076923